retatrutide moa RETATRUTIDE: A Medication for Diabetes and Weight Loss cagrilintide moa vs Retatrutide Compared

Key Insight: The contribution to total spend on GLP-1s for members with obesity without a diabetes diagnosis has grown significantly, now constituting almost 16.5% of spend on these drugs compared to 11% in 2022 and just 4% in 2020

75 KanoskiS

Placement precision matters Not all areas under the tongue are equal

Wade, K

These ingredients may provide modest appetite support through different pathways but lack the potent metabolic and satiety effects documented in clinical trials for genuine GLP-1 agonists

Both drugs are administered through injection and are typically prescribed when diet and exercise alone are not sufficient to control blood sugar levels in people with type 2 diabetes, or in the case of Wegovy, weight